Svetlana Mojsov discussed GLP-1 drug research findings with Luke O'Neill, referencing technology foundations laid in the 1980s.
1 report, 1 independent
Updated Sep 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Svetlana Mojsov discussed GLP-1 drug research findings with Luke O'Neill, referencing technology foundations laid in the 1980s.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Novo Nordisk received approval in China for Wegovy, while Chinese drugmakers are developing their own GLP-1 medicines.
- Novo Nordisk's Wegovy rollout is planned for Germany as GLP-1 therapies shift consumer priorities.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.